Perspectives for the immune plasma treatment of COVID-19.

Creative Commons License

Sayinalp B., Çinar O. E., HaznedaroĞlu İ. C.

Turkish journal of medical sciences, cilt.51, ss.1-9, 2021 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 51
  • Basım Tarihi: 2021
  • Doi Numarası: 10.3906/sag-2005-410
  • Dergi Adı: Turkish journal of medical sciences
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.1-9
  • Anahtar Kelimeler: COVID-19, pandemic, convalescent plasma, ANTIBODY, SARS, INFLUENZA, THERAPY
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Background/aim: The SARS-CoV-2 infection was declared as a pandemic by the World Health Organization (WHO) on March 11, 2020, and the death toll from COVID-19, which is the disease caused by SARS-CoV-2, has already surpassed that of many previous epidemics. A wide variety of treatment options are being considered for COVID-19, but there is still no definitive treatment or vaccine. This study aims to explain the background of convalescent plasma (CP) treatment and its relations with COVID-19 immunity, to define ideal treatment procedures, and to reveal present and future perspectives in the light of the rapidly growing data.